From e03015f06faa761502f9ff937984d19cb14f05a9 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 11 May 2026 04:20:47 +0000 Subject: [PATCH] vida: extract claims from 2025-12-12-utmb-uthealth-texas-ibogaine-impact-50m-oud - Source: inbox/queue/2025-12-12-utmb-uthealth-texas-ibogaine-impact-50m-oud.md - Domain: health - Claims: 2, Entities: 1 - Enrichments: 2 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida --- ...ardiac-safety-delays-approval-4-5-years.md | 20 ++++++ ...tituency-transcending-partisan-politics.md | 18 +++++ entities/health/texas-impact-consortium.md | 71 +++++++++++++++++++ ...-uthealth-texas-ibogaine-impact-50m-oud.md | 5 +- 4 files changed, 113 insertions(+), 1 deletion(-) create mode 100644 domains/health/ibogaine-oud-evidence-strongest-psychedelic-addiction-application-but-cardiac-safety-delays-approval-4-5-years.md create mode 100644 domains/health/texas-conservative-state-psychedelic-research-enabled-by-veteran-constituency-transcending-partisan-politics.md create mode 100644 entities/health/texas-impact-consortium.md rename inbox/{queue => archive/health}/2025-12-12-utmb-uthealth-texas-ibogaine-impact-50m-oud.md (98%) diff --git a/domains/health/ibogaine-oud-evidence-strongest-psychedelic-addiction-application-but-cardiac-safety-delays-approval-4-5-years.md b/domains/health/ibogaine-oud-evidence-strongest-psychedelic-addiction-application-but-cardiac-safety-delays-approval-4-5-years.md new file mode 100644 index 000000000..e9d0c5df4 --- /dev/null +++ b/domains/health/ibogaine-oud-evidence-strongest-psychedelic-addiction-application-but-cardiac-safety-delays-approval-4-5-years.md @@ -0,0 +1,20 @@ +--- +type: claim +domain: health +description: "MAPS Phase 2 shows 70-75% abstinence at 1 month with single-dose opioid withdrawal abolition, but QT prolongation risk and >30 deaths require extended safety protocols" +confidence: experimental +source: UTMB/UTHealth Texas IMPACT announcement, MAPS Phase 2 data, Stanford 2024 veterans study +created: 2026-05-11 +title: Ibogaine demonstrates strongest single-session evidence for opioid use disorder among psychedelics but cardiac safety requirements delay FDA approval 4-5 years beyond psilocybin +agent: vida +sourced_from: health/2025-12-12-utmb-uthealth-texas-ibogaine-impact-50m-oud.md +scope: causal +sourcer: UTMB Health / UTHealth Houston +supports: ["americas-declining-life-expectancy-is-driven-by-deaths-of-despair-concentrated-in-populations-and-regions-most-damaged-by-economic-restructuring-since-the-1980s"] +challenges: ["the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access"] +related: ["psilocybin-achieves-positive-phase3-trd-single-dose-26week-durability", "glp-1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "americas-declining-life-expectancy-is-driven-by-deaths-of-despair-concentrated-in-populations-and-regions-most-damaged-by-economic-restructuring-since-the-1980s", "ibogaine-federal-policy-priority-rests-on-single-n30-pilot-illustrating-veteran-constituency-acceleration-ahead-of-evidence-hierarchy"] +--- + +# Ibogaine demonstrates strongest single-session evidence for opioid use disorder among psychedelics but cardiac safety requirements delay FDA approval 4-5 years beyond psilocybin + +The Texas IMPACT consortium ($50M state + $50M federal) represents the largest state-sponsored psychedelic research investment targeting opioid use disorder, the highest-mortality addiction crisis (79,384 overdose deaths in 2024). MAPS Phase 2 trials demonstrate 70-75% abstinence at 1 month, and ibogaine uniquely abolishes opioid withdrawal symptoms within 1-2 days through opioid receptor reset and GDNF-mediated dopaminergic neuron regeneration. However, ibogaine remains Schedule I with no completed Phase 3 trial, while psilocybin has two positive Phase 3 trials for treatment-resistant depression with rolling NDA submission Q4 2026. The critical barrier is cardiac safety: ibogaine causes QT prolongation with >30 documented deaths in unsupervised settings, requiring extensive safety protocols that extend the regulatory timeline. Texas IMPACT is Phase 2 scale (multi-site, two-year duration), meaning Phase 3 initiation depends on these results, with realistic NDA submission 2029-2030. The urgency-evidence-access gap is widest for ibogaine: strongest evidence for the most acute crisis, but furthest from approval due to safety requirements that psilocybin's cleaner profile avoids. diff --git a/domains/health/texas-conservative-state-psychedelic-research-enabled-by-veteran-constituency-transcending-partisan-politics.md b/domains/health/texas-conservative-state-psychedelic-research-enabled-by-veteran-constituency-transcending-partisan-politics.md new file mode 100644 index 000000000..fe2fa044f --- /dev/null +++ b/domains/health/texas-conservative-state-psychedelic-research-enabled-by-veteran-constituency-transcending-partisan-politics.md @@ -0,0 +1,18 @@ +--- +type: claim +domain: health +description: Texas authorized $50M for ibogaine research through veteran-focused framing (Stanford n=30 study in veterans) where psilocybin depression research might have failed politically +confidence: experimental +source: Texas SB 2308 (December 2025), Trump EO April 2026 directing ARPA-H funding toward ibogaine for veterans +created: 2026-05-11 +title: Conservative state psychedelic research authorization is enabled by veteran constituency that transcends partisan politics rather than general mental health advocacy +agent: vida +sourced_from: health/2025-12-12-utmb-uthealth-texas-ibogaine-impact-50m-oud.md +scope: structural +sourcer: UTMB Health / UTHealth Houston +related: ["psilocybin-achieves-positive-phase3-trd-single-dose-26week-durability", "ibogaine-federal-policy-priority-rests-on-single-n30-pilot-illustrating-veteran-constituency-acceleration-ahead-of-evidence-hierarchy", "stanford-ibogaine-veterans-study", "trump-2026-psychedelic-executive-order-creates-bipartisan-regulatory-acceleration-through-existing-frameworks"] +--- + +# Conservative state psychedelic research authorization is enabled by veteran constituency that transcends partisan politics rather than general mental health advocacy + +Texas represents the most conservative large state in the US, yet authorized $50M for Schedule I psychedelic drug research through SB 2308 in December 2025, with potential $50M federal ARPA-H match directed by Trump executive order in April 2026. The political enabling mechanism is veteran-specific: the Stanford 2024 study (n=30) demonstrated 88% PTSD reduction and 87% depression reduction in veterans specifically, and the Texas IMPACT consortium explicitly targets PTSD and TBI alongside OUD. Veterans represent a constituency that transcends partisan politics in ways that general mental health populations do not. The PTSD+TBI+veteran framing made ibogaine acceptable to Texas Republicans where psilocybin for depression in general populations likely would not have secured equivalent funding. This creates a distinct political pathway for psychedelic research: veteran-focused applications can access conservative state funding and federal support (Trump EO) that wellness or general mental health applications cannot. The Trump administration's ARPA-H directive and DEA rescheduling commitment upon Phase 3 completion further demonstrates bipartisan federal support when framed through veteran health rather than broader mental health reform. diff --git a/entities/health/texas-impact-consortium.md b/entities/health/texas-impact-consortium.md new file mode 100644 index 000000000..2f9a59b90 --- /dev/null +++ b/entities/health/texas-impact-consortium.md @@ -0,0 +1,71 @@ +--- +type: entity +entity_type: research_program +name: Texas IMPACT Consortium +full_name: Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma +domain: health +status: active +founded: 2025-12 +headquarters: Texas, USA +website: null +tags: [ibogaine, OUD, PTSD, TBI, psychedelic, clinical-trial, Texas] +--- + +## Overview + +The Texas IMPACT (Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma) Consortium represents the largest state-sponsored psychedelic research investment in US history, with $50 million from Texas Health and Human Services Commission plus up to $50 million ARPA-H federal match for a potential $100 million total. + +## Structure + +**Lead institutions:** UTHealth Houston and UTMB Health (Galveston) + +**Consortium members (11 institutions):** +- UTHealth Houston +- UTMB Health +- Texas Tech University +- Texas Tech UTHS El Paso +- UT Austin +- UT Health Science Center San Antonio +- UT Tyler +- UT Rio Grande Valley +- Texas A&M University +- University of North Texas Health Science Center +- Baylor College of Medicine +- JPS Health Network (Dallas) + +## Research Design + +**Duration:** Two-year multicenter trial (Phase 2 scale) + +**Conditions targeted:** +- Opioid use disorder (primary indication) — UTHealth Houston + UTMB +- Traumatic brain injury — UT Austin + Baylor College of Medicine +- PTSD — coordinated across sites + +**Key evidence basis:** +- Stanford 2024 study (n=30 veterans): 88% PTSD reduction, 87% depression reduction at 1 month +- MAPS Phase 2 OUD: 70-75% abstinence at 1 month +- Mechanism: Opioid receptor reset + GDNF production → dopaminergic neuron regeneration +- Unique capability: Abolishes opioid withdrawal symptoms within 1-2 days + +## Regulatory Context + +**Current status:** Ibogaine is Schedule I (federal) with no completed Phase 3 trial in US + +**Safety barrier:** QT prolongation risk with >30 documented deaths in unsupervised settings + +**Political support:** +- Texas SB 2308 (December 2025): Authorized $50M state funding +- Trump EO (April 2026): Directed ARPA-H funding toward ibogaine for veterans; DEA to initiate rescheduling upon Phase 3 completion +- Colorado Proposition 122: Decriminalized in Colorado + +## Timeline + +- **2025-12** — Texas SB 2308 authorizes $50M state funding for IMPACT consortium +- **2026-04** — Trump executive order directs ARPA-H to provide up to $50M federal match and commits DEA to rescheduling process upon Phase 3 completion + +## Significance + +The Texas IMPACT consortium addresses the opioid overdose crisis (79,384 deaths in 2024), the most acute public health emergency in mental health/substance use. Ibogaine is the only psychedelic with credible single-session evidence for OUD specifically. The program demonstrates bipartisan political support through veteran-focused framing, with conservative Texas authorizing the largest state psychedelic research investment in US history. + +Realistic FDA approval timeline: 2029-2030 if Phase 2 data supports Phase 3 advancement, making ibogaine 4-5 years behind psilocybin despite addressing higher-mortality condition. \ No newline at end of file diff --git a/inbox/queue/2025-12-12-utmb-uthealth-texas-ibogaine-impact-50m-oud.md b/inbox/archive/health/2025-12-12-utmb-uthealth-texas-ibogaine-impact-50m-oud.md similarity index 98% rename from inbox/queue/2025-12-12-utmb-uthealth-texas-ibogaine-impact-50m-oud.md rename to inbox/archive/health/2025-12-12-utmb-uthealth-texas-ibogaine-impact-50m-oud.md index 6315ea8c8..574064e7e 100644 --- a/inbox/queue/2025-12-12-utmb-uthealth-texas-ibogaine-impact-50m-oud.md +++ b/inbox/archive/health/2025-12-12-utmb-uthealth-texas-ibogaine-impact-50m-oud.md @@ -7,10 +7,13 @@ date: 2025-12-12 domain: health secondary_domains: [] format: press-release -status: unprocessed +status: processed +processed_by: vida +processed_date: 2026-05-11 priority: medium tags: [ibogaine, OUD, PTSD, TBI, Texas, clinical-trial, psychedelic, addiction, federal-funding] intake_tier: research-task +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content